AAA
LYRA

Affinity Asset Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Affinity Asset Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$570K – 77
2020
Q4 		$570K Buy
+1,000
New +$563K 0.3% 55

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's LYRA Position: Q1 2021 in Review

Affinity Asset Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2021, closing a stake of 1,000 shares — an estimated $570K sold.

Affinity Asset Advisors first reported a position in LYRA in Q4 2020 and held it in 1 quarter. The position peaked at $570K in Q4 2020. 49 funds tracked by Wall St. Rank hold LYRA as of Q1 2021.

  • Affinity Asset Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 1,000 LYRA THERAPEUTICS INC shares in Q1 2021, an estimated $570K.
  • Affinity Asset Advisors first reported a position in LYRA THERAPEUTICS INC in Q4 2020 and held it in 1 quarter.
  • Affinity Asset Advisors's LYRA THERAPEUTICS INC position peaked at $570K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2021.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.